Witnessing the stock’s movement on the chart, on Wednesday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) set off with pace as it heaved 3.49% to $9.19, before settling in for the price of $8.88 at the close. Taking a more long-term approach, AUPH posted a 52-week range of $5.20-$10.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Nevertheless, stock’s Earnings Per Share (EPS) this year is 1365.00%. This publicly-traded company’s shares outstanding now amounts to $137.75 million, simultaneously with a float of $119.37 million. The organization now has a market capitalization sitting at $1.24 billion. At the time of writing, stock’s 50-day Moving Average stood at $8.21, while the 200-day Moving Average is $8.13.
Aurinia Pharmaceuticals Inc (AUPH) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Aurinia Pharmaceuticals Inc’s current insider ownership accounts for 11.64%, in contrast to 45.19% institutional ownership. According to the most recent insider trade that took place on Mar 07 ’25, this organization’s Chief Medical Officer sold 8,305 shares at the rate of 8.23, making the entire transaction reach 68,350 in total value, affecting insider ownership by 153,484. Preceding that transaction, on Mar 03 ’25, Company’s Chief Executive Officer sold 195,593 for 8.00, making the whole transaction’s value amount to 1,564,744. This particular insider is now the holder of 1,953,892 in total.
Aurinia Pharmaceuticals Inc (AUPH) Earnings and Revenue Records
Aurinia Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 1365.00% and is forecasted to reach 0.76 in the upcoming year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Let’s observe the current performance indicators for Aurinia Pharmaceuticals Inc (AUPH). It’s Quick Ratio in the last reported quarter now stands at 5.26. Alongside those numbers, its PE Ratio stands at $33.27, and its Beta score is 1.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.02. Similarly, its price to free cash flow for trailing twelve months is now 19.68.
In the same vein, AUPH’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.28, a figure that is expected to reach 0.14 in the next quarter, and analysts are predicting that it will be 0.76 at the market close of one year from today.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Going through the that latest performance of [Aurinia Pharmaceuticals Inc, AUPH]. Its last 5-days volume of 1.79 million indicated improvement to the volume of 1.47 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 69.39% While, its Average True Range was 65.34%.
Raw Stochastic average of Aurinia Pharmaceuticals Inc (AUPH) in the period of the previous 100 days is set at 93.12%, which indicates a major rise in contrast to 91.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.40 that was higher than 0.31 volatility it exhibited in the past 100-days period.
